Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by BioNxt Solutions Inc.
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
October 19, 2026
From
BioNxt Solutions Inc.
Via
ACCESS Newswire
Tickers
BNXTF
CSE:BNXT
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
September 08, 2026
From
BioNxt Solutions Inc.
Via
ACCESS Newswire
Tickers
BNXTF
CSE:BNXT
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
August 19, 2026
From
BioNxt Solutions Inc.
Via
ACCESS Newswire
Tickers
BNXTF
CSE:BNXT
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
August 17, 2026
From
BioNxt Solutions Inc.
Via
ACCESS Newswire
Tickers
BNXTF
CSE:BNXT
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
August 04, 2026
From
BioNxt Solutions Inc.
Via
ACCESS Newswire
Tickers
BNXTF
CSE:BNXT
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
July 06, 2026
From
BioNxt Solutions Inc.
Via
ACCESS Newswire
Tickers
BNXTF
CSE:BNXT
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1